

Osteoarthritis and Cartilage



Review

Role of C-type natriuretic peptide signalling in maintaining cartilage and bone function



N.J. Peake †, A.J. Hobbs ‡, B. Pingguan-Murphy §, D.M. Salter ||, F. Berenbaum ¶, T.T. Chowdhury †*

† Institute of Bioengineering, School of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London E1 4NS, UK

‡ William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK

§ Department of Biomedical Engineering, Faculty of Engineering, University of Malaya, 50603 Kuala Lumpur, Malaysia

|| Centre for Genomics and Experimental Medicine, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road, Edinburgh EH4 2XU, UK

¶ Sorbonne Universités, Université Pierre et Marie Curie Paris 06, INSERM UMRS 938, Assistance Publique-Hopitaux de Paris, Department of Rheumatology and DHU i2B, Hôpital Saint-Antoine, Paris, France

ARTICLE INFO

Article history:

Received 19 March 2014

Accepted 22 July 2014

Keywords:

Osteoarthritis

Inflammation

C-type natriuretic peptide

Natriuretic peptide receptor

Cartilage homeostasis

SUMMARY

C-type natriuretic peptide (CNP) has been demonstrated in human and mouse models to play critical roles in cartilage homeostasis and endochondral bone formation. Indeed, targeted inactivation of the genes encoding CNP results in severe dwarfism and skeletal defects with a reduction in growth plate chondrocytes. Conversely, cartilage-specific overexpression of CNP was observed to rescue the phenotype of CNP deficient mice and significantly enhanced bone growth caused by growth plate expansion. *In vitro* studies reported that exogenous CNP influenced chondrocyte differentiation, proliferation and matrix synthesis with the response dependent on CNP concentration. The chondroprotective effects were shown to be mediated by natriuretic peptide receptor (Npr)2 and enhanced synthesis of cyclic guanosine-3',5'-monophosphate (cGMP) production. Recent studies also showed certain homeostatic effects of CNP are mediated by the clearance inactivation receptor, Npr3, highlighting several mechanisms in maintaining tissue homeostasis. However, the CNP signalling systems are complex and influenced by multiple factors that will lead to altered signalling and tissue dysfunction. This review will discuss the differential role of CNP signalling in regulating cartilage and bone homeostasis and how the pathways are influenced by age, inflammation or sex. Evidence indicates that enhanced CNP signalling may prevent growth retardation and protect cartilage in patients with inflammatory joint disease.

© 2014 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.

Introduction

Articular joint function is known to be dependent on the homeostasis of multiple tissue types. Bones develop and grow into adulthood through the expansion and differentiation of chondrocytes at the cartilaginous growth plate through a process known as endochondral ossification. Initially, mesenchymal precursor cells condense in the centre and undergo differentiation into large chondrocytes that proliferate in a longitudinal manner characteristic of the growth plate¹. The cells eventually stop proliferating and

undergo terminal differentiation into hypertrophic chondrocytes that ultimately promote the vascularisation, mineralisation and recruitment of osteoclasts and osteoblasts which replace the calcified cartilage matrix with bone². The process of hyaline cartilage formation that covers the articular surface leads to the deposition of extracellular matrix components and provides the structural properties that facilitate normal joint biomechanics. In turn, biomechanical signals promote beneficial anabolic activities in chondrocytes facilitating normal remodelling mechanisms and tissue homeostasis. However, in age-related diseases of the joint, the integrity of the extracellular matrix is lost, leading to disruption of cell function, abnormal signalling and reduced load-bearing function. Indeed, weakening of bone structure leads to osteoporosis (OP) and loss of cartilage integrity results in osteoarthritis (OA).

* Address correspondence and reprint requests to: T.T. Chowdhury, School of Engineering and Materials Science, Queen Mary University of London, Mile End Road, London E1 4NS, UK. Tel: 44-(0)207-8827560.

E-mail address: t.t.chowdhury@qmul.ac.uk (T.T. Chowdhury).

It is well recognised that C-type natriuretic peptide (CNP) regulates cardiac and vascular function³, promoting homeostatic effects involving hyperpolarisation and cell proliferation in a manner dependent on the cell type and concentration^{4–7}. CNP is distinct from other natriuretic peptides, with emerging evidence for its ability to regulate cartilage and bone homeostasis. The development of transgenic mouse models that target the CNP signalling system has helped to define the importance of this peptide in cartilage and bone^{8–18}. In clinical studies, dwarf patients with acromesomelic dysplasia, type Maroteaux (AMDM) were found to have autosomal recessive *Npr2* functional deletions leading to stunted skeletal growth but no deficiency in CNP levels¹⁹. In addition, *Npr2* functional haploinsufficiency that occurs in family members of AMDM patients were reported to have short stature²⁰. This is in contrast to CNP overproduction which has been associated with bone overgrowth and skeletal deformations^{21,22}. Human genome-wide association studies have demonstrated a link between CNP and height variation and circulating CNP levels predict height, with a close correlation to linear growth in healthy children^{23,24}. Accordingly, plasma CNP levels are at a maximum at puberty, and gradually decline into adulthood²⁵. The importance of the natriuretic peptide signalling pathway in the musculoskeletal system is therefore evident in both animals and humans. Consequently, there has been great interest in the biological effects of CNP and their influence on tissue homeostasis. In this review, we will discuss the role of CNP signalling in bone and cartilage tissues and how homeostatic functions may be influenced by age, inflammation or sex and lead to the onset and development of joint disease.

CNP/*Npr2* signalling is critical for bone homeostasis

The skeletal defects observed in CNP and natriuretic peptide receptor (*Npr*) knockout mouse models are summarised in Table I and highlight the major phenotypes of CNP signalling in bone. CNP binds to two cell-surface receptors, *Npr2* and *Npr3*, which are expressed in osteoblasts as well as chondrocytes. The effects of CNP are mediated via *Npr2*, which possesses guanylyl cyclase (GC) activity and leads to synthesis of cyclic guanosine-3',5'-monophosphate (cGMP). Deletion of *Npr2* mimics the skeletal defects associated with loss of CNP and defective *Npr2* is responsible for dwarfism in patients with AMDM¹⁹ and subsequently confirmed in

animal models with loss of function mutation of the *Npr2* gene in the *cn/cn* mouse¹⁷. In addition, carrier parents of children with AMDM were noted to be shorter than average^{20,26}. Recent studies have also shown loss of function mutation in *Npr2* leading to severe dwarfism, skeletal dysplasia and infertility in AMDM patients^{8,17,27,28}. In animal studies, targeted disruption of genes encoding CNP showed severe dwarfism and early death as a result of impaired endochondral ossification characterised by a defective growth plate^{9,12–14}. The inhibition in growth plate chondrocytes caused a 10% reduction in length in contrast to intramembranous bones which were of normal size⁹. In contrast, overstimulation of *Npr2*/GC causes skeletal overgrowth disorders^{11,15,29,30}. *Npr3* does not possess GC functionality, but acts as a clearance inactivation receptor and subjects natriuretic peptides to lysosomal degradation, thereby regulating *Npr2* signalling²⁹. Indeed, deletion of *Npr3* in mice supports this model with significant overgrowth observed, most notably leading to distinctive arching of the back²⁹. Furthermore, cartilage specific over-expression of CNP in growth plate chondrocytes rescued the phenotype of *Nppc*-deficient mice¹¹. For example, no significant differences were observed in the naso-anal length between *tg/Nppc*^{-/-} mice and *Nppc*^{+/+} mice⁹, clearly indicating that CNP is critical for bone formation.

The impact of the CNP signalling pathway *in vitro* appears to be dependent on the model system and celltype (Table II). Previous studies showed that CNP stimulated cell differentiation by increasing gene expression for alkaline phosphatase and osteocalcin and mineralisation of nodules in osteoblastic MC3T3-E1 cells and osteoblast-like cells from newborn rat calvaria^{31–33}. These observations are consistent with the effects of CNP in primary cultures of fetal rat calvaria where the peptide induced osteoblast differentiation and showed synergy with factors such as osteogenic protein-1 (OP-1)³⁴. The enhanced bone growth in mouse tibia cultured with CNP increased cGMP signalling through *Npr2*, and influenced the MEK (MAP/ERK kinase) Erk 1/2 kinase and p38 mitogen activated protein kinase (MAPK) cascades³⁵. Recent studies reported differential effects of CNP on cell proliferation with the response dependent on the cell type^{36,37}. In an earlier study, CNP was shown to activate osteoclast bone resorption activities in a cGMP-dependent manner in osteoclast containing mouse bone marrow cultures³⁸. It is possible that the bone marrow cultures treated with CNP forced the undifferentiated stem cells in these cultures towards chondrogenesis via endochondral bone growth

Table I
In vivo evidence indicating a role for CNP/*Npr* signalling in the skeleton

Genotype	Phenotype	Reference
<i>Nppc</i> ^{-/-}	<ul style="list-style-type: none"> - 10% loss of body weight at birth - 30–40% reduction of growth - No significant differences in organ/body weight - Stunted tail/bones - 50% birth rate - Reduced skull size and shortened jaws - Size and mortality rescued by systemic over-expression of CNP 	[9–11]
<i>Npr3</i> ^{-/-}	<ul style="list-style-type: none"> - Increased circulating ANP and ANP half-life - Normal birth rate, but 50% mortality before weaning - Enhanced urine production and water intake - Hunched backs, dome-shaped skull, elongated tails and bones - Increased body length - Decreased weight 	[29]
<i>FGFR3</i> ^{-/-}	<ul style="list-style-type: none"> - Achondroplasia rescued by targeted cartilage-specific CNP expression and by systemic CNP over-expression 	[62]
<i>Prkg</i> ^{-/-}	<ul style="list-style-type: none"> - Dwarfism not rescued by targeted CNP over-expression, therefore linking CNP to cGKI signalling 	[13]
<i>Lbab/Lbab</i>	<ul style="list-style-type: none"> - Long bone abnormality caused by a spontaneous mutation in CNP leading to reduced (30–100 fold) binding to <i>Npr2</i> - Rescued by cartilage-specific expression of CNP 	[14–16]
<i>cn/cn</i>	<ul style="list-style-type: none"> - Spontaneous missense mutation in <i>Npr2</i> leading to dwarfism, short limbs and tail due to defective endochondral ossification - Notable lack of cGMP production in response to CNP 	[17]
<i>CNP</i> ^{col2a1TG} and <i>K/BxN</i> TCR	<ul style="list-style-type: none"> - Inflammatory arthritis model displaying growth delay, diminished chondrocyte proliferation and ECM synthesis - Symptoms rescued by cartilage-specific expression of CNP 	[18]

Download English Version:

<https://daneshyari.com/en/article/3379419>

Download Persian Version:

<https://daneshyari.com/article/3379419>

[Daneshyari.com](https://daneshyari.com)